Technical Analysis for NRSNW - NeuroSense Therapeutics Ltd. - warrant
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.20 | 0.00% | 0.00 |
NRSNW closed unchanged on Tuesday, May 7, 2024, on 54 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Down 3% | 1 day ago |
| Down 2 % | 1 day ago |
| Down 1% | 1 day ago |
| Outside Day | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/01/2022
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Senescence Treatment Of Alzheimer's Disease Neurodegenerative Disease Clinical Neuroscience
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Treatment Of Parkinson's Disease Senescence Treatment Of Alzheimer's Disease Neurodegenerative Disease Clinical Neuroscience
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.64 |
| 52 Week Low | 0.073 |
| Average Volume | 11,042 |
| 200-Day Moving Average | 0.23 |
| 50-Day Moving Average | 0.30 |
| 20-Day Moving Average | 0.33 |
| 10-Day Moving Average | 0.25 |
| Average True Range | 0.07 |
| RSI (14) | 41.18 |
| ADX | 23.68 |
| +DI | 18.87 |
| -DI | 28.10 |
| Chandelier Exit (Long, 3 ATRs) | 0.34 |
| Chandelier Exit (Short, 3 ATRs) | 0.40 |
| Upper Bollinger Bands | 0.52 |
| Lower Bollinger Band | 0.14 |
| Percent B (%b) | 0.16 |
| BandWidth | 115.61 |
| MACD Line | -0.03 |
| MACD Signal Line | -0.01 |
| MACD Histogram | -0.0181 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.26 | ||||
| Resistance 3 (R3) | 0.26 | 0.25 | 0.25 | ||
| Resistance 2 (R2) | 0.25 | 0.23 | 0.24 | 0.25 | |
| Resistance 1 (R1) | 0.22 | 0.22 | 0.22 | 0.22 | 0.24 |
| Pivot Point | 0.21 | 0.21 | 0.20 | 0.21 | 0.21 |
| Support 1 (S1) | 0.18 | 0.19 | 0.18 | 0.18 | 0.16 |
| Support 2 (S2) | 0.17 | 0.18 | 0.17 | 0.15 | |
| Support 3 (S3) | 0.14 | 0.17 | 0.15 | ||
| Support 4 (S4) | 0.14 |
